30th week of 2018 patent applcation highlights part 9 |
Patent application number | Title | Published |
20180207182 | DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis. | 2018-07-26 |
20180207183 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents. | 2018-07-26 |
20180207184 | METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLS - The disclosure provides methods of treating cancer by selectively inhibiting p-S | 2018-07-26 |
20180207185 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE - Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine. | 2018-07-26 |
20180207186 | FORMULATION OF GLUCOSINOLATES AND MYROSINASE - Disclosed is a formulation which contains microcapsules which contain a core containing an extract rich in glucosinolates obtained from crucifers and a biopolymer, and an enteric coating containing myrosinase and a biopolymer. Also, disclosed is a procedure for obtaining the same and to a use of the formulation as such, or in dietetic food supplements for humans or animals due to its immunostimulant activity. | 2018-07-26 |
20180207187 | COMPOSITION FOR OPTIC NERVE PROTECTION - A composition for optic nerve cell protection, for preventing or treating glaucoma, for suppressing retinal ganglion cell death, or for delaying a progression of visual acuity loss of human contains at least one selected from the group consisting of products obtained by steaming and drying wheat, defatted wheat germ, defatted rice germ, defatted soybean, fermented grape, hesperidin, lactic acid bacterium | 2018-07-26 |
20180207188 | TREATMENT OF PAPULOPUSTULAR ROSACEA WITH IVERMECTIN - Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments. | 2018-07-26 |
20180207189 | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE - Provided herein are alpha2-selective Na,K-ATPase inhibitors and prodrugs thereof, characterized by having a cyclic moiety attached to a digoxin or digitoxin derivative, as well as uses thereof in lowering intraocular pressure and in treating glaucoma and heart conditions. | 2018-07-26 |
20180207190 | COMPOSITION CONTAINING NAD FOR PREVENTING AND TREATING OBESITY OR IMPAIRED GLUCOSE TOLERANCE - A pharmaceutical composition containing nicotinamide adenine dinucleotide (NAD) as an active ingredient for preventing and treating obesity or impaired glucose tolerance, a food composition, and a method for preventing and treating obesity or impaired glucose tolerance using the same is disclosed. The NAD remedies an abnormal food intake pattern of an obese animal model induced by the intake of a high-fat diet and increases mobility, thereby exhibiting an effect of suppressing the weight increase due to the high-calorie intake and also showing an effect of improving glucose tolerance. In addition, it was verified that the NAD is capable of maintaining the above effects with even a much smaller quantity than an NAD precursor known in the prior art. Therefore, the composition containing NAD can be favorably used as a pharmaceutical composition or a food composition capable of effectively preventing and treating obesity or impaired glucose tolerance. | 2018-07-26 |
20180207191 | HUMAN CANCER MICRO-RNA EXPRESSION PROFILES PREDICTIVE OF CHEMO-RESPONSE - Disclosed are identified and successfully targeted microRNAs (miRNAs) associated with human cancer cell line response to a range of anti-cancer agents. The strategy of integrating in vitro miRNA expression and drug sensitivity data not only aid in the characterization of determinants of cytotoxic response, but also in the identification of novel therapeutic targets. | 2018-07-26 |
20180207192 | SUBSTANCE AND METHOD FOR MODULATING PROLIFERATION AND DIFFERENTIATION OF REGULATORY, STEM AND OTHER SOMATIC CELLS - The invention relates to the field of basic biology, practical regenerative medicine, veterinary, cell biology and can be used to treat and prevent diseases, disorders or conditions associated with the violation of proliferation and differentiation of cells of different organs and tissues to activate the regeneration potential of human and animal organs and tissues at age- related changes and after extreme impacts, as well as for biomedical research. The present invention can be widely applied in the field of blood transfusion, organ transplantation, as well as serve as a general approach to the development of reliable methods to correct age-related changes in the elderly. The invention may also be used in the cosmetic industry for producing active ingredients for enhancing regeneration and improving the scalp, face and body, in particular for the manufacture of active additives to combat deep wrinkles, removal of skin defects, stimulation and acceleration of hair growth, controlling hirsutism, etc. | 2018-07-26 |
20180207193 | COMPOSITIONS AND METHODS FOR IMPROVING ENZYME REPLACEMENT THERAPY FOR LYSOSOMAL STORAGE DISEASES - The present disclosure provides compositions and methods for improving the efficacy of enzyme replacement therapy for lysosomal storage diseases. | 2018-07-26 |
20180207194 | OXIDIZED B-1,4-OLIGOGLUCURONIC ACID, AND PREPARATION METHOD THEREFOR AND USES THEREOF - An oxidized β-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. By using abundant cellulose in the natural world as the raw material, all 6-site hydroxyl groups of the cellulose β-1,4-polyglucose is oxidized into carboxyl groups to form glucuronic acid under the action of a sodium bromide (NaBr)-2,2,6,6-tetramethyl piperidine oxide (TEMPO)-sodium hypochlorite (NaClO) oxidation system, and the oxidized oligoglucuronic acid having an open ring at an end is prepared by controlling reaction conditions. The compound has obvious anti-cerebral ischemia activity, and can be developed into a potential anti-cerebral ischemia drug. | 2018-07-26 |
20180207195 | OXIDIZED A-1,4-OLIGOGLUCURONIC ACID, AND PREPARATION METHOD THEREFOR AND USES THEREOF - An oxidized α-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. By using abundant starch, especially soluble starch, in the natural world as the raw material, all 6-site hydroxyl groups of the starch α-1,4-polyglucose are oxidized into carboxyl groups to form glucuronic acid under the action of a sodium bromide (NaBr)-2,2,6,6-tetramethyl piperidine oxide (TEMPO)-sodium hypochlorite (NaClO) oxidation system, and the oxidized oligoglucuronic acid having an open ring at an end is prepared by controlling reaction conditions. The compound has obvious anti-cerebral ischemia activity, and can be developed into a potential anti-cerebral ischemia drug. | 2018-07-26 |
20180207196 | METHODS RELATING TO LUNG CANCER - The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs. | 2018-07-26 |
20180207197 | OLIGONUCLEOTIDE DERIVATIVE - The present invention provides an oligonucleotide derivative having, at an oxygen atom of at least one phosphate group of an oligonucleotide, a group represented by formula (I): | 2018-07-26 |
20180207198 | COMPOSITIONS BASED ON METHYL CYCLODEXTRINS FOR THE TREATMENT AND/OR PREVENTION OF DISEASES BY INCREASING THE HDL CHOLESTEROL LEVEL - Pharmaceutical composition and their uses are disclosed, the composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level. | 2018-07-26 |
20180207199 | NEW USE OF HYALURONIC ACID - A gel containing hyaluronic acid in a crosslinked form or in a mixture of a crosslinked and non-crosslinked form is injected into the periosteum of a bone in order to heal and/or regenerate bones or tissue surrounding bones in humans or vertebrates. | 2018-07-26 |
20180207200 | DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF - The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation. | 2018-07-26 |
20180207201 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2018-07-26 |
20180207202 | METHODS FOR MOBILIZING HEMATOPOIETIC STEM CELLS - Disclosed are methods of mobilizing hematopoietic cells in a subject by administering to the subject a combination of Flt3 ligand (FLT3L) and a cell adhesion inhibitor. Also disclosed are methods of mobilizing hematopoietic cells in a cell culture population by contacting the cell culture population with Flt3 ligand. Mobilized hematopoietic cells can subsequently be harvested and used for hematopoietic cell transplantation. Further disclosed are compositions comprising a FLT3L, compositions comprising FLT3L and a cell adhesion inhibitor, and composition comprising FLT3L and Plerixafor. | 2018-07-26 |
20180207203 | PORTABLE APPARATUS WITH MIXING DEVICE AND METHODS RELATING TO COLLECTING AND PROCESSING HUMAN BIOLOGICAL MATERIAL COMPRISING ADIPOSE - A portable apparatus for collection and processing of human biological material containing adipose, such as extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with an internal containment volume including an available processing volume in a range of from 75 cubic centimeters to 1300 cubic centimeters, and with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. The apparatus has a mixing device for mixing contents within the tissue retention volume, and including a rotatable shaft extending from outside of the internal containment volume to inside of the internal containment volume and comprises at least one mixing member that is disposed in the tissue retention volume and is connected with the shaft to move through the tissue retention volume relative to the filter when the shaft is rotated. Methods include use of the apparatus to process human biological material containing adipose, such as to prepare a stromal vascular fraction concentrate product or a fat graft composition. | 2018-07-26 |
20180207204 | KRILL OIL PREPARATIONS WITH OPTIMAL MINERAL AND METAL COMPOSITION, LOW IMPURITIES AND LOW AND STABLE TMA LEVELS - A Krill oil preparation including a reduced amount of trimethylamine of 5 mgN/100 g or less, or more than 700 ppm by weight of endogenous calcium and/or less than 1200 ppm by weight of sodium. A process of making such a Krill oil preparation that includes a step of extracting Krill oil from Krill with a solvent mixture of one or more polar solvents and one or more non-polar solvents. A method of treating a human in need of treatment that includes administering to the human an amount of such a Krill oil preparation. | 2018-07-26 |
20180207205 | Compositions and Methods of Using Krill Powder in Cardiovascular Regulation - The present invention is related to the regulation of the cardiovascular system. In particular, to krill powder compositions and their administration to mammal for regulation of blood pressure. | 2018-07-26 |
20180207206 | TREATMENT TO PROMOTE WOUND HEALING - The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains | 2018-07-26 |
20180207207 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation. | 2018-07-26 |
20180207208 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - Provided are compositions comprising a bacterial strain of the genus | 2018-07-26 |
20180207209 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS - This invention relates to new uses of | 2018-07-26 |
20180207210 | LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION - The use of a bacterium of the species | 2018-07-26 |
20180207211 | RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED IN TRANS - The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans. | 2018-07-26 |
20180207212 | USE OF ONCOLYTIC HERPES SIMPLEX VIRUS, ALONE OR IN COMBINATION WITH IMMUNE CHECK-POINT INHIBITOR, IN THE TREATMENT OF CANCER - An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a Th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor. | 2018-07-26 |
20180207213 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME - Antiviral pharmaceutical compositions comprising one or more cannabinoid compounds in the form of lip-balms, creams and ointments. A specific embodiment provides a topical composition formulated as a lip-balm. | 2018-07-26 |
20180207214 | Reproductive Cell Maintenance System - Extracts obtained from the genus | 2018-07-26 |
20180207215 | SHENLINGBAIZHU GRANULES AND PREPARATION METHOD THEREOF - Disclosed are shenlingbaizhu granules and a preparation method thereof, wherein the shenlingbaizhu granules comprise an extract of raw material medicines and excipients, the raw material medicines being: 400 parts by weight of ginseng, 400 parts by weight of tuckahoe, 400 parts by weight of | 2018-07-26 |
20180207216 | Compositions and Methods for Treating Multi-Drug Resistant Malaria - A method is provided for treating an individual for a malarial infection, in particular drug-resistant species of | 2018-07-26 |
20180207217 | Method for Relieving Memory Dysfunction Using Puerariae Radix Extract - A method for relieving memory dysfunction using Puerariae Radix Extract is provided, including decocting Puerariae Radix in water, concentrating the extracted product thereof, and administrating an effective dose of the Puerariae Radix extract to a subject. Since the present invention merely uses Puerariae Radix as an ingredient, it belongs to a Chinese herbal medicine of single drug prescription. Further, with the same amount of Puerarin, Puerariae Radix Extract of the present invention provides a better neuroprotective effect in comparison with Puerarin, which indicates that the Puerariae Radix extract contains more active neurotrophic ingredients other than Puerarin. Therefore, Puerariae Radix extract is more promising potential therapeutic medicine than Puerarin for relieving the symptoms of anxiety and cognitive impairment. | 2018-07-26 |
20180207218 | PLANT EXTRACTIONS, COMPOSITIONS CONTAINING SAME, AND USES THEREOF - This disclosure relates to plant extracts selected from | 2018-07-26 |
20180207219 | CHINESE MEDICINE HANGOVER CURING AGENT - A Chinese medicine hangover curing agent. The agent is prepared from Chinese Hawthorn, Folium nelumbinis, Folium mori, Taraxaci herba, Lophatheri herba, common duckweed and tangerine leaves. | 2018-07-26 |
20180207220 | Sour Cherry Topical Therapeutic Formulations, Method of Manufacture and Method of Treatment of Human Osteoarthritis Symptoms - A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by CD3+ T lymphocytes in a vertebrate mammal. | 2018-07-26 |
20180207221 | Sour Cherry Topical Therapeutic Formulations, Method of Manufacture and Method of Treatment of Human Osteoarthritis Symptoms - A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by CD3+ T lymphocytes in a vertebrate mammal. | 2018-07-26 |
20180207222 | COMPOSITION FOR ALLEVIATING SKIN INFLAMMATION CAUSED BY YELLOW DUST AND FINE PARTICULATE, COMPRISING NATURAL PLANT EXTRACT - The present invention relates to a composition comprising natural plant extracts for alleviating inflammation caused by yellow dust and fine particulate, wherein the plant extracts of the present invention inhibit a production of NO caused by the yellow dust and fine particulate and a production of inflammatory cytokines, thus having an excellent effect on preventing or alleviating skin inflammation caused by the yellow dust, fine particulate and other harmful substances. | 2018-07-26 |
20180207223 | PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USE - The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, inflammatory diseases or inflammatory response to infection. | 2018-07-26 |
20180207224 | APPLICATION OF DIPEPTIDE AS ACE ENZYME ACTIVITY INHIBITOR - An application of dipeptide as an ACE enzyme activity inhibitor. Virtual screening is performed on 400 types of dipeptide based on ACE inhibiting effects thereof according to a detected ACE enzyme crystal structure by using self-developed software and adopting a molecular docking method, experiments are conducted to verify the ACE inhibitory activity of the dipeptide obtained by virtual screening, and it finds out that the dipeptide with the N terminal as cysteine has better ACE inhibitory activity. | 2018-07-26 |
20180207225 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA - The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof. | 2018-07-26 |
20180207226 | COMPOSITIONS AND METHODS FOR INHIBITION OF BACTERIAL INFECTIONS IN HUMAN ENDOCERVIX - Provided are compositions, methods and devices for prophylaxis and/or therapy of sexually transmitted bacterial infections that infect the female reproductive tract. The compositions methods and devices are used for intravaginal administration of compositions that contain a peptide agent known as PIK and/or a compound known as ML-7. Demonstrations of embodiments are provided for infection models that involve | 2018-07-26 |
20180207227 | Therapeutic and Neuroprotective Peptides - Nonnatural peptides and their methods of use in human or non-human animal subject to cause an effect such as: nuroprotection, protecting against or lessening nerve impairment or damage, treating glaucoma, treating age-related macular degeneration or other inherited or acquired retinal degenerations, enhancing retinal tissue repair, enhancing retinal regenerative therapy through activation of innate immune cells or treating inherited or acquired retinal degeneration | 2018-07-26 |
20180207228 | PEPTIDE COMBINATIONS AND USES THEREOF FOR TREATING GRASS ALLERGY - The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species. | 2018-07-26 |
20180207229 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE - The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative. | 2018-07-26 |
20180207230 | AUTOCLAVABLE SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations. | 2018-07-26 |
20180207231 | POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE LACKING A GLYCOSYLATION SIGNAL - The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid. | 2018-07-26 |
20180207232 | Soy-Derived Bioactive Peptides for Use in Compositions and Methods for Wound Healing, Tissue Engineering, and Regenerative Medicine - Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile. | 2018-07-26 |
20180207233 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS - The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age-related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders. | 2018-07-26 |
20180207234 | INHIBITION OF CANCER GROWTH AND METASTASIS - The present invention relates to methods for treating or preventing cancer and metastasis. More particularly, the present invention relates to methods for treating or preventing cancer by decreasing the expression and/or activity of Flightless I. Also provided are methods for inhibiting the growth of a cancerous cell and methods for inhibiting formation and/or growth of a tumour which also rely on decreasing the expression and/or activity of Flightless I. The present invention also extends to methods for diagnosing cancer, methods for determining if a subject is susceptible to developing cancer, and methods for assessing progression of cancer based on the finding that increased expression and/or activity of Flightless I is associated with cancer development, growth and metastasis. The present invention also provides methods for screening for a candidate therapeutic agent useful for treating or preventing cancer, and related pharmaceutical compositions and kits. | 2018-07-26 |
20180207235 | NEUROPROTECTIVE AGENTS DERIVED FROM SPIDER VENOM PEPTIDES - The invention relates to disulfide-rich peptides derived from spider venom and their use, particularly as neuroprotective agents. The invention also relates to nucleic acid molecules encoding the peptides as well as constructs and host cells comprising those nucleic acid molecules. | 2018-07-26 |
20180207236 | METHODS AND COMPOSITIONS USING GDF15 POLYPEPTIDES FOR INCREASING RED BLOOD CELLS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2018-07-26 |
20180207237 | IL-12 FORMULATIONS FOR ENHANCING HEMATOPOIESIS - Provided are formulations for proteins to be injected into mammals. Specifically, formulations for recombinant IL-12 in mice and primates. | 2018-07-26 |
20180207238 | COMPOSITIONS AND METHODS FOR REGULATING LEUKOCYTE ADHESION - Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulating leukocytes. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by tumor necrosis factor α (TNF α). This process involves activation of Type 1 TNF receptors, recruitment of Src Family Kinases (SFK), and SFK-dependent phosphorylation of Panx1. We report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation. The present application further discloses that Panx IL2 peptide consisting of amino acid sequence KYPIVEQYLKYGRKKQRR (SEQ ID NO: 3) or | 2018-07-26 |
20180207239 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA - The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component. | 2018-07-26 |
20180207240 | COLLAGEN IV REPLACEMENT - Disclosed are pharmaceutical compositions, formulations, and methods for treating Alport syndrome by administering recombinant human collagen IV protein to a patient in need. | 2018-07-26 |
20180207241 | PEPTIDE HAVING FIBROSIS INHIBITORY ACTIVITY AND COMPOSITION CONTAINING SAME - The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-β signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis. | 2018-07-26 |
20180207242 | Treatment of Cognitive Impairment of Mucopolysaccharidosis Type IIIA by Intrathecal Delivery of Heparan N-Sulfatase - The present invention provides, among other things, effective treatment for Sanfilippo Syndrome Type A (MPS IIIA) based on intrathecal delivery of recombinant heparan N-sulfatase (HNS) enzyme. The present invention also includes methods of treating Sanfilippo Syndrome Type A (MPS IIIA) Syndrome by intrathecal administration of a recombinant HNS enzyme at a therapeutically effective dose and an administration interval for a period sufficient to decrease glycosaminoglycan (GAG) heparan sulfate level in the cerebrospinal fluid (CSF) relative to baseline (e.g., prior to treatment) as well as to improve, stabilize, or reduce decline of cognitive function, disability, behavior, quality of life and/or auditory brainstem response relative to baseline (e.g., prior to treatment). | 2018-07-26 |
20180207243 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of treating a subject having or at risk for having an HIV-1 virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and causing neither genotoxicity nor off-target editing to the host. | 2018-07-26 |
20180207244 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 2018-07-26 |
20180207245 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 2018-07-26 |
20180207246 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY - A method for preventing bleeding, blood-brain barrier disruption, brain injury, or a combination thereof in a subject destined for cardiac surgery is disclosed. The method involves administering to the subject prior to cardiac surgery a therapeutically effective amount of alpha-1 antitrypsin (AAT-1), or functional variant thereof. The result is that it prevents bleeding, blood-brain barrier disruption, or a combination thereof in a subject destined for cardiac surgery. | 2018-07-26 |
20180207247 | METHODS OF TRANSPLANTATION AND DISEASE TREATMENT - A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided. | 2018-07-26 |
20180207248 | COMPOSITIONS AND METHODS FOR MODULATING AND/OR STIMULATING IMMUNE RESPONSES IN HUMAN AND/OR ANIMAL - There is provided a composition including parietal polysaccharides from at least one | 2018-07-26 |
20180207249 | METHOD AND VACCINE COMPRISING COPOLYMER 1 FOR TREATMENT OF PSYCHIATRIC DISORDERS - Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide; and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions. | 2018-07-26 |
20180207250 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INDUCING IMMUNE TOLERANCE BY MUCOSAL VACCINATION WITH FC-COUPLED ANTIGENS - The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety. | 2018-07-26 |
20180207251 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2018-07-26 |
20180207252 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS - A method of treating a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule. | 2018-07-26 |
20180207253 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS - A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule. | 2018-07-26 |
20180207254 | HLA-DR-BINDING ANTIGEN PEPTIDE DERIVED FROM WT1 - The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide. | 2018-07-26 |
20180207255 | IMMUNOGENIC COMPOSITIONS CONTAINING BACTERIAL OUTER MEMBRANE VESICLES - This invention relates to outer membrane vesicles (OMVs) from Gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane. The OMVs of the invention are capable of eliciting an immune response to the heterologous protein or to a fragment thereof when administered to a mammal. Other aspects of the invention relate to methods of preparing the OMVs and immunogenic compositions containing the same. | 2018-07-26 |
20180207256 | NOVEL TARGETS OF ACINETOBACTER BAUMANNII - The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as | 2018-07-26 |
20180207257 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 11 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections. | 2018-07-26 |
20180207258 | ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 2018-07-26 |
20180207259 | BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE - Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. | 2018-07-26 |
20180207260 | PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE - The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided. | 2018-07-26 |
20180207261 | HUMAN HERPESVIRUS IMMUNOTHERAPY - An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens. | 2018-07-26 |
20180207262 | PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent | 2018-07-26 |
20180207263 | TREATMENT OF CANCER WITH NALTREXONE - The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonised. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone. | 2018-07-26 |
20180207264 | PORCINE IMMUNE MODULATION MODEL - A method of modulating an immune response. The method includes administering a treatment comprising delta 5-androsten-3B, 17B-diol, delta 5-androsten-3B, 7B, 17B-triol, or both. | 2018-07-26 |
20180207265 | A NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME - The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders. | 2018-07-26 |
20180207266 | MODULATION OF TUMOR IMMUNITY - Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided. | 2018-07-26 |
20180207267 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF - Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation. | 2018-07-26 |
20180207268 | COMBINATION THERAPY FOR CANCER - The present invention relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2- dihydropyridine-3-carboxamide, and to methods of using the combination to treat certain disorders, such as gastric cancer. | 2018-07-26 |
20180207269 | Methods of Treating CD166-Expressing Cancer - It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)-also known as CD166-is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof. | 2018-07-26 |
20180207270 | Methods of Using Interleukin-10 for Treating Diseases and Disorders - Methods of modulating immune responses in subjects having oncology- and immune-related diseases, disorders and conditions by the administration of an IL-10 agent, including pegylated IL-10. | 2018-07-26 |
20180207271 | IL-26 INHIBITORS - The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections. | 2018-07-26 |
20180207272 | GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY - An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed. | 2018-07-26 |
20180207273 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 - Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders. | 2018-07-26 |
20180207274 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain. | 2018-07-26 |
20180207275 | TOPICAL FORMULATIONS AND TREATMENTS - Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol. | 2018-07-26 |
20180207276 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF - Methods and compositions are provided for extending the half-life of a therapeutic agent. One half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents comprising a half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof. | 2018-07-26 |
20180207277 | Stable Fat-soluble Active Ingredient Composition, Microcapsule and Process Of Preparation and Use Thereof - The present invention provides a stable fat-soluble active ingredient composition, microcapsule and process for preparation and use thereof. The fat-soluble active ingredient composition comprises tocopherol, vitamin C palmitate and a fat-soluble active ingredient; wherein the weight ratio of tocopherol to vitamin C palmitate is 2-8:1, the weight ratio of a combination of tocopherol with vitamin C palmitate to the fat-soluble active ingredient is 7-13:100. The present invention obtains a novel antioxidant composition without hidden dangers for improving the stability of the fat-soluble active ingredient by screening a combination of antioxidants and adjusting their proportion and dose. | 2018-07-26 |
20180207278 | LIQUID FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND - The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided. | 2018-07-26 |
20180207279 | METHODS OF TREATING ULCERATIVE COLITIS - Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo. | 2018-07-26 |
20180207281 | POLYSACCHARIDE-BASED HYDROGELS AND HYBRID HYDROGELS AND PRECURSORS THEREOF, METHODS OF MAKING SAME, AND USES THEREOF - Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers). | 2018-07-26 |
20180207282 | GUMMY DOSAGE FORMS COMPRISING SERINE - The present disclosure describes a gummy dosage form including: an amino acid in an amount of about 20% by weight or greater; a hydrophilic bulking agent; and a hydrophilic long-chain polymer, wherein at least a portion of the hydrophilic long-chain polymer comprises low methoxyl pectin. The gummy dosage forms can further include additives such as flavorants, fiber, and pH-adjusters. The disclosure further comprises methods for preparing such gummy dosage forms, wherein a hydrophilic bulking agent, a hydrophilic long-chain polymer, and water are combined to give a mixture and heated to give a hydrocolloid system in the form of a slurry; mixing an amino acid with the slurry; and setting the resulting mixture to give the gummy dosage form. | 2018-07-26 |